The Technical AnalystExchange: HKSE Sector: Biotechnology Industry: Biotechnology
Shanghai Henlius Biotech Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.60% HKD16.80
America/New_York / 3 mai 2024 @ 02:50
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 8 922.95 mill |
| EPS: | 1.110 |
| P/E: | 15.14 |
| Earnings Date: | Mar 21, 2024 |
| SharesOutstanding: | 531.13 mill |
| Avg Daily Volume: | 0.233 mill |
| RATING 2024-05-02 |
|---|
| A |
| Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Sell | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Buy | |
| DE: | Strong Buy | |
| P/E: | Neutral | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | |||||
| Gr.Profit | n/a | |||||
| Ebit | n/a | |||||
| Asset | n/a | n/a | ||||
| Debt | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 1.60x |
| Company: PE 15.14 | sector: PE 9.44 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0.43x |
| Company: PE 15.14 | industry: PE 35.62 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
HKD 16.19 - 17.41 ( +/- 3.61%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | HKD16.80 (0.60% ) |
| Volume | 0.293 mill |
| Avg. Vol. | 0.233 mill |
| % of Avg. Vol | 125.93 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For 2696.HK
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
2696.HK
Shanghai Henlius Biotech, Inc., a biopharmaceutical company, engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases. It offers HANLIKANG, a rituximab injection for treating non-hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis; HANQUYOU, a trastuzumab injection to treat breast and metastatic gastric cancer; HANDAYUAN, an adalimumab injection for the treatment of rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, and uveitis; HANBEITAI, a bevacizumab injection to treat metastatic colorectal cancer (mCRC) and non-squamous non-small cell lung cancer (nsNSCLC); and HANSIZHUANG, a serplulimab injection for microsatellite instability-high solid tumors. The company also develops Serplulimab to treat squamous non-small cell lung cancer (sqNSCLC), extensive small-cell lung cancer, metastatic esophageal squamous-cell carcinomas, neo-/adjuvant treatment of gastric cancer, hepatocellular carcinoma, mCRC, nsNSCLC, squamous cell carcinoma of the head and neck (SCCHN), and solid tumors; HLX04-O, a bevacizumab injection for wet age-related macular degeneration; HLX22 to treat breast and metastatic gastric cancer; HLX07, HLX23, HLX35, HLX208, HLX55, HLX301, and HLX20 for the treatment of solid tumors; HLX11 to treat breast cancer; HLX05, a cetuximab injection for mCRC and SCCHN; HLX12 for gastric cancer, metastatic non-small cell lung cancer, and mCRC; and HLX14 to treat osteoporosis. In addition, it develops HLX26 for the treatment of solid tumor and lymphoma; HLX13 to treat melanoma, renal cell carcinoma, and mCRC; HLX15 for multiple myeloma; and HLX71 to treat COVID-19. Shanghai Henlius Biotech, Inc. operates in Mainland China, Europe, rest of Asia Pacific, and internationally. The company was founded in 2010 and is headquartered in Shanghai, China. Shanghai Henlius Biotech, Inc. is a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.